請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35026完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李水盛 | |
| dc.contributor.author | Hsin-Yi Hung | en |
| dc.contributor.author | 洪欣儀 | zh_TW |
| dc.date.accessioned | 2021-06-13T06:39:06Z | - |
| dc.date.available | 2008-08-12 | |
| dc.date.copyright | 2005-08-12 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-08-07 | |
| dc.identifier.citation | 1. http://www.plantzafrica.com/plantab/asparagdens.htm (Kirstenbosch National Botanical Garden)
2. http://www.ces.ncsu.edu/depts/hort/consumer/poison/Asparde.htm (North Carolina State University) 3. Toshikazu S., Fumio I., Nobuaki F., Yumi K., Tatsuo A., Yuichi F., Nijsiri R., and Isamu M. Structure and Relative Stereochemistry of a New Polycylic Alkaloid, Asparagamine A, Showing Anti-oxytocin Activity, Isolated from Asparagus racemosus Chem. Pharm. Bull. 42(6) 1360-1362 (1994) 4. Peter M., Jozsef D., Gyula T., Adrian H., Hanspeter P., and Kurt B. (9Z)-Capsanthin-5,6-epoxide, a New Carotenoid from the Fruits of Asparagus falcatus J. Nat. Prod. 64, 1254-1255 (2001) 5. Oketch-Rabah H. A., Dossaji S. F., Brogger C. S., Karla F., Else L., Claus C., Carl E. O., Ming C.,Arsalan K., and Thor T. Antiprotozal Compounds from Asparagus africanus; J. Nat. Prod. 60, 1017-1022 (1997) 6. Zhou Z. L., Rita A., Francesco D. S., Antonio D., Oreste S., and Cosimo P. Oligofurostanosides from Asparagus cochinchinensis Planta medica 54, 344 (1988) 7. Asfaw D., Ernst H., Olaf K., Gunter M., and Dawit A. Steroidal Saponin from Asparagus africanus Phytochemistry 51, 1069-1075(1999) 8. Yu S., Onoomar P., Edward J. K., Chee-Kok C., Chi-Tang H., Mou-Tuan H., Stephen A. G., and Geoffrey A. C. Steroidal Saponin from Asparagus officinalis and Their Cytotoxic Activity Planta Medica 63, 258-262 (1997) 9. Sharma S. C., Sati O. P., and Chand R. Steroidal Saponin of Asparagus curillus Phtochemistry 21, 1711-1714 (1982) 10. Ke h., Xinsheng Y. Protodioscin(NSC-698 796): Its Spectrum of Cytotoxic Against Sixty Human Cancer Cell Lines in an Anticancer Drug Screen Panel Planta medica 68, 297-301 (2002) 11. Antonio G. G., Juan C. H., Franciso L., Juan I. P., Francisco E., Jose Q., and Jaime B. Steroidal Saponin from the Bark of Dracaena draco and Their Cytotoxic Activities J. Nat. Prod. 66, 793-798 (2003) 12. Yoshihiro M., Tadaaki S., Minpei K., Yutaka S., and Yoshio H.; Steroidal Saponin from the Bulb of Lilium candidum Phytochemistry 51, 567-573 (1999) 13. 吳立軍主編, 天然藥物化學 (第四版), 北京; 人民衛生出版社, 2003 14. Wall M. E., Eddy C. R., Mcclennen M. L., and Klumpp M. E. Anal. Chem. 24, 1377(1952) 15. Pawan K. A. Spectral Assignments and Reference Data Magn. Reson. Chem. 24, 990-993 (2004) 16. Tsuyoshi I., Hidetsugu T., Masafumi O., and Toshihiro N. Pregnane- and Furostane-Type Oligoglycosides from the Seeds of Allium tuberosum Chem. Pharm. Bull. 52, 142-145(2004) 17. Agrawal P.K., Jain D. C., Gupta R. K., and Thakur R. S. Carbon-13 NMR Spectroscopy of Steroidal Sapogenins and Steroidal Saponins Phytochemistry 24, 2479-2496(1985) 18. Masazumi M., Yukiyoshi T., Hitoshi M., Kenji M., Osamu T., Takao I., Kazuhiro O., Ryoji K., and kazup Y. Antiyeast Steroidal Saponins from Yucca schidigera (Mohave Yucca), a New Anti-Food-Deteriorating Agent J. Nat. Prod. 63, 332-338(2000) 19. Paul M Dewick; Medicinal Natural Product : A biosynthetic approach (2nd ed.), Great Britain: Wily pp237-241 (2001) 20. Silverstein, Robert M.; Spectrometric identification of organic compounds (6th ed.), United States : Wily p.225 (1997) 21. Snyder, Lloyd R.; Practical HPLC method development (2nd ed.), United State：Wiley (1997) 22. Tsuyoshi I., Hidetsugu T., Takehiko H., and Toshihiro N. Cytooxic Activity of Steroidal Glycosides from Solanum Plants Biol. Pham. Bull. 26, 1198-1201(2003) 23. Akihito Y., Yoshihiro M., and Yutaka S. Spirostanol Saponins from the rhizomes of Tacca chantrieri and Their Cytotoxic Activity Phytochem. 61, 73-78(2002) 24. Sheng-Min S., Min-Liang Z., Xiong-Wen Z., Ai-Na L., and Zhong-Liang C. Tuberoside M, A New Cytotoxic Spirostanol Saponin from the Seeds of Allium Tuberosum J. Asia Nat. Prod. Res. 4, 69-71(2002) 25. 徐任生主編, 天然產物化學 (第二版), 北京; 科學出版社, 2004 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35026 | - |
| dc.description.abstract | 先前的研究顯示百合科植物蘆筍(Asparagus officinalis)的種子具有抗癌活性的甾體皂苷，因此我們想去探討同屬植物但尚無研究報告的常見庭園植物天門冬(A. densiflorus)是否具有相似的抗癌活性成分。
將去子之果實以水萃取，繼之以極性分割為乙酸乙酯層、丁醇層及水層。而丁醇層，經由離心式分配層析儀及Sephadex LH-20進行劃割得到富含甾體皂苷的部份，再以半製備高效液相層析管柱RP-18分離(MeOH-H2O, ACN-H2O)而得五個甾体皂苷，包括26-O-β-D-glucopyranosyl-22α-methoxy-(25S)-furostan-3β,26-diol 3-O-α-L-rhamopyranosyl-(1→4)-β-D-glucopyranoside (1), 26-O-β-D-glucopyranosyl-22α-methoxy-(25R)-furostan-3β,26-diol 3-O-α-L-rhamopyranosyl-(1→4)- β-D-glucopyranoside (2), 26-O-β-D-glucopyranosyl-22α-hydroxy-(25R)-furostan-3β,26-diol 3-O-[α-L-rhamnopyranosyl-(1→2)- α-L-rhamopyranosyl-(1→4)]- β-D-glucopyranoside} (3), (25R,S)-5β-spirost-5-en-3β-ol 3-O-α-L-rhamnopyranosyl-(1→4)- β-D-glucopyranoside (4), (25S)-5β-spirostan-3-ol 3-O -α-L-rhamnopyranosyl-(1→2)- α-L-rhamnopyranosyl-(1→4)- β-D-glucopyranoside (5) 這些成分之結構皆經光譜分析確認，其中化合物1、3為首次分離的之天然物。而化合物5具有抗乳癌細胞(MCF-7)活性，IC50為5.19 μg/ml。 | zh_TW |
| dc.description.abstract | Recent studies indicated that the seed of Asparagus officinalis (Liliaceae) contained cytotoxic steroidal glycosides. Hence, we wanted to explore whether a related and uninvestigated species, A. densiflorus, a common garden plant, contained similar bioactive constituents.
The water extract of the fresh fruits void of seeds was divided into fractions soluble in EtOAC, n-BuOH and H2O. The n-BuOH soluble part was further fractionated over centrifugal partition chromatography (CPC), and Sephadex LH-20 to give fractions rich in glycosides. Separation of these fractions via semipreparative RP-18 HPLC column (MeOH-H2O, ACN-H2O) led to the isolation of five glycosides. They are characterized as 26-O-β-D-glucopyranosyl-22α-methoxy-(25S)-furostan-3β,26-diol 3-O-α-L-rhamopyranosyl-(1→4)-β-D-glucopyranoside (1), 26-O-β-D-glucopyranosyl-22α-methoxy-(25R)-furostan-3β,26-diol 3-O-α-L-rhamopyranosyl-(1→4)- β-D-glucopyranoside (2), 26-O-β-D-glucopyranosyl-22α-hydroxy-(25R)-furostan-3β,26-diol 3-O-[α-L-rhamnopyranosyl-(1→2)- α-L-rhamopyranosyl-(1→4)]- β-D-glucopyranoside} (3), (25R,S)-5β-spirost-5-en-3β-ol 3-O-α-L-rhamnopyranosyl-(1→4)- β-D-glucopyranoside (4), (25S)-5β-spirostan-3-ol 3-O -α-L-rhamnopyranosyl-(1→2)- α-L-rhamnopyranosyl-(1→4)- β-D-glucopyranoside (5)Their structures were elucidated mainly by NMR spectral analysis. This study leads to the isolation and characterization of two new furostanoid glycosides(1, 3). In addition, compound 5 is demonstrated to possess cytotoxicity against breast cancer cell line (MCF-7) with IC50 value of 5.19 μg/ml。 | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T06:39:06Z (GMT). No. of bitstreams: 1 ntu-94-R92423006-1.pdf: 14205939 bytes, checksum: 12432dfe85325d9bcc74e04c78c1d420 (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 中文摘要…………………………………………………………………………… I
英文摘要……………………...……………………………………..…………….. II 總目錄………………………….………………………………………………… III 表目錄 (List of Tables)……..….…………………………………………………. V 流程圖目錄 (List of scheme)….………………………………………………… VI 圖及附圖目錄 (List of Figures and Spectra Appendices)……………………… VII 辭彙 (Glossary)………………………………………………………………… XV 壹、 序論及研究目的…………………………………………………………. 1 1.1武竹植物之簡介……………………………………………………… 1 1.2天門冬植物成分之相關研究………………………………………… 2 1.3甾體皂苷的化學結構………………………………………………… 6 1.4偵測器的介紹及比較………………………………………………… 8 1.5 製備級HPLC的介紹及注意事項………………………………..... 11 1.6研究目的…………………………………………………………..… 13 貳、 研究結果與討論………………………………………………………… 15 2.1分離結果…………………………………………………………… 15 2.1.1丁醇層CPC分離結果………………………………………….. 15 2.1.2 CPC Fr.A 之Sephadex LH-20分離結果………………………. 16 2.1.3 Fr.AS-3之成分分離結果……………………………………….. 18 2.1.4 CPC Fr.B之Sephadex LH-20分離結果……………………… 23 2.1.5 Fr.BS-2之成分分離結果……………………………………… 24 2.1.6 Fr.BS-3之成分分離結果……………………………………… 25 2.1.7 Fr.AS-4之成分分離結果……………………………………… 26 2.2結構解析……………………………………………………………. 28 2.2.2 Furost-5-ene-3,22,26-triol類化合物1及化合物2之結構解析. 32 2.2.1 Furostane-3,22,26-triol類化合物3之結構解析……………… 28 2.2.3 Spirost-5-en-3-ol類化合物4之結構解析…………………….. 39 2.2.4 Spirostan-3-ol類化合物5之結構解析…………………………. 43 2.3皂苷元C-22位置立體結構探討…………………………………… 47 2.4甾體皂苷類抗癌活性探討………..………………………………… 49 參、 實驗部份…………………………………………………………………… 52 3.1儀器與材料…………………………………………………………. 52 3.1.1理化性質測定儀器…………………………………………… 52 3.1.2成分分析及分離之儀器及材料……………………………… 52 3.1.3 試劑與溶劑……………………………………………………. 52 3.2武竹果實部醣苷類之抽取與分離…………………………………. 53 3.2.1丁醇層之成分分離 …………………………………………… 55 3.2.2 CPC Fr. A之成分分離………………………………………… 55 3.2.3 Fr. AS-3之成分分離…………………………………………... 56 3.2.4 CPC Fr. B之成分分離………………………………………… 57 3.2.5 Fr. BS-2之成分分離………………………………………….. 57 3.2.6 Fr. BS-3之成分分離………………………………………….. 57 3.2.7 Fr. AS-4之成分分離………………………………………….. 58 3.3各成分之理化數據………………………………………………… 58 肆、參考文獻………………………………………………………………….. 60 附圖 表目錄 (List of Tables) Table 1. 13C NMR chemical shifts of basic spirostanoid, furostanoid and furospirostanoid skeletons….………………………………………….. 8 Table 2. Comparison of UV, RI and ELSD ………………………………….…… 10 Table 3. Analytical vs. Preparative HPLC: Difference in Goals and Characteristics...11 Table 4. 1H- and 13C-NMR spectral data of compound 1 (aglycon part) ……… 30 Table 5. 1H- and 13C-NMR spectral data of compound 1 (sugar part) ………… 31 Table 6. Comparison of 1H- and 13C-NMR spectral data of compound 1 and 2 (aglycon part) ………………………………………………………….. 32 Table 7. Analysis of C-25 configuration of compound 1 and 2………………... 33 Table 8. 1H- and 13C-NMR spectral data of compound 3 (aglycon part) ……….. 38 Table 9. 1H- and 13C-NMR spectral data of compound 3 (sugar part)…………... 39 Table 10. 1H- and 13C-NMR spectral data of compound 4 (aglycon part) …….. 41 Table 11. 1H- and 13C-NMR spectral data of compound 4 (sugar part) ……… 42 Table 12. 1H- and 13C-NMR spectral data of compound 5 (aglycon part) ……… 45 Table 13. 1H- and 13C-NMR spectral data of compound 5 (sugar part) ………….. 46 Table 14. SAR study of spirostanoid against PC-12 and HCT-116 cancer cell lines…………………………………………………………………….. 49 Table 15. In vitro anti-hepotoma activity of crude extract………………......... 167 Table 16. Anti-breast cancer activity of constituents isolated from Fr. AS-4… 168 流程圖目錄 (List of scheme) Scheme 1. Extraction and fractionation of the fruit of Asparagus densiflorus….. 53 Scheme 2. Separation of BuOH layer containing steroidal glycosides………….. 54 圖及附圖目錄 (List of Figures and Spectra Appendices) Figure 1.蒸發光散射檢測器(Evaporative Light Scattering Detector)結構示意圖.. 9 Figure 2. Hypothetical separations as a function of sample weight……………. 12 Figure 3. 丁醇可溶物之CPC分離結果之矽膠TLC圖示…………………… 15 Figure 4. 丁醇可溶物Fr. A之DCCC分離結果之矽膠TLC圖示………….. 16 Figure 5. 丁醇可溶物Fr. A之Lobar Lichroprep. RP-8分離結果之矽膠TLC圖 示…………………………………………………………………….. 16 Figure 6. 丁醇可溶物Fr. A之Sephadex LH-20分離結果之矽膠TLC圖示…. 17 Figure 7. 高液相層析儀分析Fr. AS-3之層析圖 (動相：ACN-water)……….. 18 Figure 8. 高液相層析儀分析Fr. AS-3之層析圖 (動相：MeOH-water)…….. 19 Figure 9. 半製備級高液相層析儀分離示意圖………………………………... 20 Figure 10. 高液相層析儀分離Fr. AS-3之層析圖…..……………………….. 21 Figure 11. 丁醇可溶物Fr. B之Sephadex LH-20分離結果之矽膠TLC圖示… 23 Figure 12. 高液相層析儀分離Fr. BS-2之層析圖……………………………... 24 Figure 13. 高液相層析儀分離Fr. BS-3之層析圖…..…………………………. 25 Figure 14. 高液相層析儀分析Fr. AS-4之層析圖……………………………... 26 Figure 15. 高液相層析儀分離Fr. AS-4之層析圖…………………………….. 27 Figure 16. Key HMBC correlation of compound 1…………………………….. 29 Figure 17. Key HMBC correlation of compound 3................................................ 37 Figure 18. NOESY cross-peak of H-5 and Me-19….…………………………… 37 Figure 19. 13C NMR data of compound 4a (25R)……………………………….. 40 Figure 20. 13C NMR data of compound 4b (25S)………………………………. 40 Figure 21. sarsasapogenin及smilagenin化學降解圖………………………….. 47 Figure 22. spirostane skeleton生合成示意圖…………………………………... 48 Figure 23. 1H spectrum of compound 1 (CD3OD, 400MHz).…………………… 63 Figure 24. Expanded 1H spectrum of compound 1 (CD3OD, 400MHz)...…….… 64 Figure 25. 13C-NMR and DEPT-90, 135 spectra of compound 1 (CD3OD, 100MHz)……………………………………………………….… 65 Figure 26. Expanded 13C-NMR spectrum of compound 1 (CD3OD, 100MHz)…... 66 Figure 27. HMBC spectrum of compound 1….…………………………………. 67 Figure 28. Expanded HMBC spectrum (1) of compound 1 (δH 0.7~2.2 ppm, δC 14~45 ppm)……………………………………...…………………. 68 Figure 29. Expanded HMBC spectrum (2) of compound 1 (δH 3.3~5.5 ppm, δC 14~45 ppm)………………………………………………………… 69 Figure 30. Expanded HMBC spectrum (3) of compound 1 (δH 0.8~2.5 ppm, δC 55~83 ppm)………………………………………………………… 70 Figure 31. Expanded HMBC spectrum (4) of compound 1 (δH 3.1~5.0 ppm, δC 60~82 ppm)……………………………………………………….... 71 Figure 32. Expanded HMBC spectrum (5) of compound 1 (δH 1.0~3.8 ppm, δC 100~145 ppm)……………………………………………………… 72 Figure 33. HMQC spectrum of compound 1….…………………………………. 73 Figure 34. Expanded HMQC spectrum (1) of compound 1 (δH 0.8~2.5 ppm, δC 14~45 ppm)………………………...…………………………….… 74 Figure 35. Expanded HMQC spectrum (2) of compound 1 (δH 3.2~4.6 ppm, δC 60~85 ppm)………………………………………………………... 75 Figure 36. COSY spectrum of compound 1………….………………………..… 76 Figure 37. Expanded COSY spectrum (1) of compound 1 (δH 0.8~2.5 ppm to δH 0.8~2.5 ppm)……………………………………………….......…… 77 Figure 38. Expanded COSY spectrum (2) of compound 1 (δH 3.1~4.5 ppm to δH 3.1~4.5 ppm)………………………………………………........….. 78 Figure 39. NOESY spectrum of compound 1……….…………………………. 79 Figure 40. Expanded NOESY spectrum (1) of compound 1 (δH 1.5~4.5 ppm to δH 3.0~5.5 ppm)………………………………………………………. 80 Figure 41. Expanded NOESY spectrum (2) of compound 1 (δH 0.8~2.5 ppm to δH 0.8~2.5 ppm)…………………………………………………..……. 81 Figure 42. 1H spectrum of compound 2 (CD3OD, 400MHz)…….……………….. 82 Figure 43. Expanded 1H spectrum of compound 2 (CD3OD, 400MHz)…….……… 83 Figure 44. 13C-NMR and DEPT-90, 135 spectra of compound 2 (CD3OD, 100MHz)……………………………………………………………… 84 Figure 45. Expanded 13C-NMR spectrum of compound 2 (CD3OD, 100MHz)….. 85 Figure 46. HMBC spectrum of compound 2…..……………………………….. 86 Figure 47. Expanded HMBC spectrum (1) of compound 2 (δH 0.7~2.5 ppm, δC 14~45 ppm)……………………………………………………….. 87 Figure 48. Expanded HMBC spectrum (2) of compound 2 (δH 0.8~2.5 ppm, δC 55~83 ppm)………………………………………………………… 88 Figure 49. Expanded HMBC spectrum (3) of compound 2 (δH 3.2~4.5 ppm, δC 100~105 ppm)……………………………………………………… 89 Figure 50. Expanded HMBC spectrum (4) of compound 2 (δH 3.4~5.5 ppm, δC 14~45 ppm)…………………………………………..…………… 90 Figure 51. Expanded HMBC spectrum (5) of compound 2 (δH 3.0~5.0 ppm, δC 60~83 ppm)………………………………………………………. 91 Figure 52. HMQC spectrum of compound 2………….…………………………... 92 Figure 53. Expanded HMQC spectrum (1) of compound 2 (δH 0.8~2.5 ppm, δC 14~45 ppm)………………………………………………………… 93 Figure 54. Expanded HMQC spectrum (2) of compound 2 (δH 3.0~4.5 ppm, δC 45~83 ppm)……………………………………………………….... 94 Figure 55. COSY spectrum of compound 2………………………………….....… 95 Figure 56. Expanded COSY spectrum (1) of compound 2 (δH 0.8~2.5 ppm to δH 0.8~2.5 ppm)……………………………………………………… 96 Figure 57. Expanded COSY spectrum (2) of compound 2 (δH 3.0~5.5 ppm to δH 3.0~5.5 ppm)……………………………………………………… 97 Figure 58. Expanded COSY spectrum (3) of compound 2 (δH 1.2~2.6 ppm to δH 3.2~5.5 ppm)……………………………………………………… 98 Figure 59. NOESY spectrum of compound 2……………………………………. 99 Figure 60. 1H spectrum of compound 3 (CD3OD, 400MHz)...………………… 100 Figure 61. Expanded 1H spectrum of compound 3 (CD3OD, 400MHz)........….. 101 Figure 62. 13C-NMR and DEPT-90, 135 spectra of compound 3 (CD3OD, 100MHz)……………………………………………………..……… 102 Figure 63. Expanded 13C-NMR spectrum (2) of compound 3 (CD3OD, 100MHz) ..103 Figure 64. HMBC spectrum of compound 3…………………………………….. 104 Figure 65. Expanded HMBC spectrum (1) of compound 3 (δH 3.0~5.5 ppm, δC 60~82 ppm)........................................................................................ 105 Figure 66. Expanded HMBC spectrum (2) of compound 3 (δH 0.5~5.5 ppm, δC 14~45 ppm)………………………………........................................ 106 Figure 67. Expanded HMBC spectrum (3) of compound 3 (δH 0.6~2.4 ppm, δC 55~85 ppm)…………………………………………......…….……. 107 Figure 68. Expanded HMBC spectrum (4) of compound 3 (δH 3.3~4.4 ppm, δC 14~45 ppm)…………………………………………......…….……. 108 Figure 69. Expanded HMBC spectrum (5) of compound 3 (δH 0.9~3.8 ppm, δC 100~115 ppm)………………………………………......…….……. 109 Figure 70. HMQC spectrum of compound 3…………………………………….. 110 Figure 71. Expanded HMQC spectrum (1) of compound 3 (δH 0.8~2.2 ppm, δC 14~45 ppm)…………………………………………...…………….. 111 Figure 72. Expanded HMQC spectrum(2) of compound 3 (δH 3.2~4.4 ppm, δC 60~85 ppm)……………………………………………………….... 112 Figure 73. Expanded HMQC spectrum (3) of compound 3 (δH 4.2~5.4 ppm, δC 100~105 ppm)…………………………………………………….... 113 Figure 74. COSY spectrum of compound 3……………………………………... 114 Figure 75. Expanded COSY spectrum (1) of compound 3 (δH 3.0~5.5 ppm to δH 3.0~5.5 ppm)………………………………………………….….... 115 Figure 76. Expanded COSY spectrum (2) of compound 3 (δH 3.6~4.5 ppm to δH 1.2~2.0 ppm)………………………………………………….….... 116 Figure 77. Expanded COSY (3) spectrum of compound 3 (δH 0.6~2.3 ppm to δH 0.6~2.3 ppm)………………………………………………….….... 117 Figure 78. NOESY spectrum of compound 3….……………………...………… 118 Figure 79. 1H spectrum of compound 4 (CD3OD, 400MHz)...………………….. 119 Figure 80. Expanded 1H spectrum of compound 4 (CD3OD, 400MHz)…...……. 120 Figure 81. 13C-NMR and DEPT-90, 135 spectra of compound 4 (CD3OD, 100MHz)……………………………………………………………… 121 Figure 82. Expanded 13C-NMR spectrum of compound 4 (CD3OD, 100MHz)… 122 Figure 83. HMBC spectrum of compound 4…………………………………… 123 Figure 84. Expanded HMBC spectrum (1) of compound 4 (δH 0.8~2.5 ppm, δC 14~45 ppm)………………………………………………………… 124 Figure 85. Expanded HMBC spectrum (2) of compound 4 (δH 0.8~2.5 ppm, δC 55~83 ppm)………………………………………………………… 125 Figure 86. Expanded HMBC spectrum (3) of compound 4 (δH 3.3~55 ppm, δC 14~55 ppm)……………………………...………………………… 126 Figure 87. Expanded HMBC spectrum (4) of compound 4 (δH 0.8~2.5 ppm, δC 14~45 ppm)……………………………..………………...………. 127 Figure 88. Expanded HMBC spectrum (5) of compound 4 (δH 1.1~3.1 ppm, δC 100~145 ppm)…………………………..………………………… 128 Figure 89. HMQC spectrum of compound 4………….………………….……… 129 Figure 90. Expanded HMQC spectrum (1) of compound 4 (δH 0.8~2.2 ppm, δC 14~35 ppm)……………………………..………………………… 130 Figure 91. Expanded HMQC spectrum (2) of compound 4 (δH 0.8~2.5 ppm, δC 35~65 ppm)……………………………..………………………… 131 Figure 92. Expanded HMQC spectrum (3) of compound 4 (δH 3.1~4.0 ppm, δC 65~83 ppm)……………………………..………………………… 132 Figure 93. Expanded HMQC spectrum (4) of compound 4 (δH 4.4~54 ppm, δC 14~45 ppm)……………………………..………………………… 133 Figure 94. COSY spectrum of compound 4……………………………...……… 134 Figure 95. Expanded COSY spectrum (1) of compound 4 (δH 0.8~2.5 ppm to δH 0.8~2.5 ppm)……………………………………………...……… 135 Figure 96. Expanded COSY spectrum (2) of compound 4 (δH 3.2~5.5 ppm to δH 1.0~2.6 ppm)………………………….……..…………………… 136 Figure 97. Expanded COSY spectrum (3) of compound 4 (δH 3.2~5.0 ppm to δH 3.0~5.0 ppm)………………………………...…………………… 137 Figure 98. NOESY spectrum of compound 4…………………………………… 138 Figure 99. Expanded NOESY spectrum (1) of compound 4 (δH 0.8~2.5 ppm to δH 0.8~2.5 ppm)………………………...…………………..………… 139 Figure 100. Expanded NOESY spectrum (2) of compound 4 (δH 3.3~5.5 ppm to δH 1.2~2.5 ppm)…………………………...……………..………… 140 Figure 101. 1H spectrum of compound 5 (CD3OD, 400MHz)…...……..……….. 141 Figure 102. Expanded 1H spectrum of compound 5 (CD3OD, 400MHz)………. 142 Figure 103. 13C-NMR and DEPT-90, 135 spectra of compound 5 (CD3OD, 100MHz)…………………………………………………………… 143 Figure 104. Expanded 13C-NMR spectrum of compound 5 (CD3OD, 100MHz).. 144 Figure 105. HMBC spectrum of compound 5…………………………………… 145 Figure 106. Expanded HMBC spectrum (1) of compound 5 (δH 0.8~2.0 ppm, δC 50~85 ppm)………………………………………………………. 146 Figure 107. Expanded HMBC spectrum (2) of compound 5 (δH 3.3~5.5 ppm, δC 60~83 ppm)…………………………..…………………….…… 147 Figure 108. Expanded HMBC spectrum (3) of compound 5 (δH 1.0~3.5 ppm, δC 100~115 ppm)…………………………………………………….. 148 Figure 109. Expanded HMBC spectrum (4) of compound 5 (δH 3.2~4.4 ppm, δC 14~45 ppm)……………………………………………………….. 149 Figure 110. HMQC spectrum of compound 5………………………………….. 150 Figure 111. Expanded HMQC spectrum (1) of compound 5 (δH 0.8~2.0 ppm, δC 14~45 ppm)……………………………………..………………… 151 Figure 112. Expanded HMQC spectrum (2) of compound 5 (δH 1.0~1.8 ppm, δC 50~70 ppm)……………………………………………………… 152 Figure 113. Expanded HMQC spectrum (3) of compound 5 (δH 3.0~4.4 ppm, δC 60~85 ppm)…………………………………………………..…… 153 Figure 114. COSY spectrum of compound 5……….…………………………… 154 Figure 115. Expanded COSY spectrum (1) of compound 5 (δH 0.8~2.2 ppm to δH 0.8~2.2 ppm)……………………………………………………… 155 Figure 116. Expanded COSY spectrum (2) of compound 5 (δH 3.2~5.0 ppm to δH 3.2~5.0 ppm)……………………………………………………… 156 Figure 117. NOESY spectrum of compound 5……….………………………… 157 Figure 118. Expanded NOESY spectrum (1) of compound 5 (δH 0.8~2.0 ppm to δH 0.8~2.0 ppm)………………………………………………….… 158 Figure 119. Expanded NOESY spectrum (2) of compound 5 (δH 3.2~5.5 ppm to δH 3.2~5.5 ppm)…………………………...……………………… 159 Figure 120. ESI Mass spectrum of compound 1…………………………...……. 160 Figure 121. ESI Mass spectrum of compound 2…………………………...……. 161 Figure 122. ESI Mass spectrum of compound 3…………………………...……. 162 Figure 123. ESI Mass spectrum of compound 4…………………………...……. 163 Figure 124. ESI Ms/Ms spectrum of compound 4…………………………….… 164 Figure 125. ESI Mass spectrum of compound 5………………………………. 165 Figure 126. ESI Ms/Ms spectrum of compound 5…………………………… 166 | |
| dc.language.iso | zh-TW | |
| dc.subject | 呋 | zh_TW |
| dc.subject | 天門冬 | zh_TW |
| dc.subject | 武竹 | zh_TW |
| dc.subject | 甾體皂苷 | zh_TW |
| dc.subject | 甾烷醇類皂苷 | zh_TW |
| dc.subject | 螺甾烷醇類皂苷 | zh_TW |
| dc.subject | furostanoid glycoside | en |
| dc.subject | Asparagus densiflorus | en |
| dc.subject | spirostanoid glycoside | en |
| dc.title | 天門冬去子果實之甾體皂苷研究 | zh_TW |
| dc.title | Studies on the Steroidal Saponins from the Deseeded Fruit of Asparagus densiflorus | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳春雄,徐鳳麟 | |
| dc.subject.keyword | 天門冬,武竹,甾體皂苷,呋,甾烷醇類皂苷,螺甾烷醇類皂苷, | zh_TW |
| dc.subject.keyword | Asparagus densiflorus,furostanoid glycoside,spirostanoid glycoside, | en |
| dc.relation.page | 168 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2005-08-08 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥學研究所 | zh_TW |
| 顯示於系所單位： | 藥學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 未授權公開取用 | 13.87 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。